Navigation Links
New Research Shows Antidepressants May Thwart Breast Cancer Treatment
Date:5/30/2009

Popular antidepressants taken with tamoxifen can increase the risk of breast cancer recurrence

PHILADELPHIA, May 30 /PRNewswire-USNewswire/ -- A new study found that taking tamoxifen with certain antidepressants more than doubled the risk of breast cancer recurrence in women taking both medications. The antidepressants inhibit an enzyme, CYP2D6, which helps tamoxifen work effectively.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090530/DC24767LOGO)

The study was conducted by researchers from Medco and the Indiana University School of Medicine and presented Saturday at the American Society of Clinical Oncology (ASCO) meeting in Orlando.

Approximately 500,000 U.S. women take tamoxifen, a medicine that blocks the effects of estrogen in breast tissue. Estrogen can make certain types of breast cancer (hormone-receptor-positive breast cancers) grow. About 30 percent of women taking tamoxifen also are taking an antidepressant to treat depression and/or to ease hot flashes, a common side effect of tamoxifen. "With more than 100,000 women potentially affected, these data represent a significant health finding," asserts Dr. Marisa Weiss, president and founder of Breastcancer.org and a breast oncologist at Lankenau Hospital in the Philadelphia area.

Preliminary, limited information from another study conducted by researchers from the Netherlands appears to offer conflicting results. The Dutch study suggests taking tamoxifen with specific antidepressants doesn't affect breast cancer recurrence rates.

"We don't want to dismiss the findings of the Dutch study; however, from what we've learned, there were fewer women in the Dutch study taking antidepressants in combination with tamoxifen, and it appears that they were taken together for a shorter period of time," says Dr. Weiss. "Regardless, there is considerable evidence in the Medco/Indiana University study, as well as in other smaller studies conducted during the past few years, to give physicians and patients reason to question using certain antidepressants (and other types of medications that might block the CYP2D6 enzyme) together with tamoxifen."

Tamoxifen has been used to successfully treat millions of women diagnosed with hormone-receptor-positive breast cancer. It can reduce the risk of cancer recurrence by about 50 percent.

"With the life-saving advantages of tamoxifen, it's imperative that women taking it derive the greatest benefit they can," says Dr. Weiss. "Women make a daily commitment to tamoxifen and deserve to get the maximum benefit this medicine affords."

She pointed out that there are safe and effective alternatives to manage depression and hot flashes that doctors can offer patients taking tamoxifen. Weiss advises women who have taken tamoxifen along with an antidepressant in the past and those who currently are taking these medicines together to talk to their doctors. Anyone with questions also can find information at Breastcancer.org.

"Since tamoxifen is the cornerstone of care for hundreds of thousands of women across the globe, this study will likely raise a lot of questions about whether to continue to use tamoxifen or change treatments, as well as whether women who stopped taking tamoxifen should restart. These new data represent an important insight into maximizing the effectiveness of breast cancer treatment," says Dr. Weiss.

About Breastcancer.org Breastcancer.org, a nonprofit organization, is the #1 online resource for medically reviewed information on breast health and breast cancer - with over 6,000 pages of medically vetted information and reaching 8 million people worldwide each year.


'/>"/>
SOURCE Breastcancer.org
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis
2. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
3. New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
4. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
5. New Federal Stem Cell Rules Would Hinder Existing Research, Consumer Group Warns
6. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
7. Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala
8. New Research Shows Nutrition 21s Chromium Histidinate Improves Markers for Mood and Carbohydrate Cravings
9. Hooters of Orange Park to Host Charity Car Wash Raising Money for Breast Cancer Research
10. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
11. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):